Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. How we score this
22 firms currently rating it, weighted by track record.
The 22 firms with a track record here beat the S&P 41% of the time over 12 months.
Pro: see the crowd-vs-sharp split for UNHThe consensus among 26 analysts is Buy, with 23 rating the stock at buy or stronger; the average price target stands at $475.23, implying 23.9% upside from current levels. JPMorgan, Morgan Stanley, and Oppenheimer maintained their bullish stances (Overweight or Outperform) in late July, though Baird upgraded from Underperform to Neutral on July 16. UnitedHealth trades at a forward P/E of 17.01 with trailing twelve-month EPS growth of 61.50%, though revenue growth remains modest at 0.40% year-over-year, and the company carries a debt-to-equity ratio of 0.69.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 21, 2026 | JPMorgan | ○ Maintained | |
| Jul 21, 2026 | Mizuho | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free